Details for Patent: 12,636,300

Which drugs does patent 12,636,300 protect, and when does it expire?

Patent 12,636,300 protects INLEXZO and is included in one NDA.

This patent has twenty-four patent family members in seventeen countries.

Drugs Protected by US Patent 12,636,300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	INLEXZO	gemcitabine hydrochloride	SYSTEM;INTRAVESICAL	219683-001	Sep 9, 2025		RX	Yes	Yes						TREATMENT OF BCG-UNRESPONSIVE, NON-MUSCLE INVASIVE BLADDER CANCER BY INTRAVESICAL ADMINISTRATION OF EQ. 225 MG GEMCITIBINE EVERY 3 WEEKS FOR 6 MONTHS FOLLOWED BY EVERY 12 WEEKS FOR UP TO 18 MONTHS

International Family Members for US Patent 12,636,300

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018366106
Brazil	112020008700
Canada	3081839